Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00670709 · ClinicalTrials.gov registry record
Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease
A clinical trial, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- 42
- Enrollment target
NCT00670709 is a clinical trial that has completed, run by University of California, Los Angeles. The registered enrollment target is 42 participants.
The verdict
NCT00670709 has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- 42 participants
- Enrollment target
Study Summary
The pace of basic science research defining the mechanisms of selective neuronal degeneration in Huntington disease (HD) has far exceeded the pace of translation of this information into clinically effective treatments for the disease. One reason for this bottleneck between bench and bedside is the paucity of available surrogate markers for HD. Identification of surrogate markers is critical for the design of future clinical trials. Such markers could provide a reliable signal of early brain dysfunction in HD and could be used as a biomarker in trials of agents that could prevent onset or delay progression of disease. Frontal-subcortical networks are known to be affected in HD and contribute to the cognitive dysfunction characteristic of the disease. Quantitative EEG (QEEG) can be used to assess the integrity of this circuitry; characteristic QEEG abnormalities long have been known to be present in the early stages of the illness (Bylsma et al., 1994). More recent research has suggested that a comprehensive topographic approach to QEEG analysis may reveal additional changes in brain activity (Bellotti et al., 2004) that may be indicative of subclinical disease (de Tommaso et al., 2003). This proposal aims to determine whether quantitative EEG techniques can be used to identify HD-specific abnormalities and thus serve as surrogate markers of disease. The goals of this pilot project are three-fold. First, we will determine if there are QEEG differences between normal control subjects and those with mild or moderate HD. Second, we will examine associations between severity of HD and the QEEG differences detected and determine if these QEEG differences are present when comparing the least affected HD subjects and normal controls. Third, we will examine associations between QEEG variables of interest and other clinical variables, including age of onset of symptoms, number of CAG repeats, severity of motor and behavioral symptoms as measured by the Unified Huntington Di
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2006-09 |
| Est. Completion | 2008-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00670709
The ClinicalTrials.gov registry entry for NCT00670709 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00670709 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00670709 about?
NCT00670709 is a clinical study titled "Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease". The pace of basic science research defining the mechanisms of selective neuronal degeneration in Huntington disease (HD) has far exceeded the pace of translation of this information into clinically effective treatments for the disease. One reason for this bottleneck between bench and bedside is the ...
What is the current status of trial NCT00670709?
This trial is currently completed. The enrollment target is 42 participants. The study started on 2006-09. Estimated completion is 2008-02.
Who is sponsoring clinical trial NCT00670709?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.